33
Participants
Start Date
January 21, 2022
Primary Completion Date
September 30, 2025
Study Completion Date
March 31, 2040
QEL-001
QEL-001 is an autologous therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against HLA-A2. Treatment will be given via an IV infusion.
RECRUITING
UZ Leuven, Leuven
RECRUITING
H. Saint Luc, Brussels
RECRUITING
Hopital Erasme, Brussels
RECRUITING
H. Clinic Barcelona, Barcelona
RECRUITING
Hospital Reina Sofia, Córdoba
RECRUITING
G. Gergorio Maranon, Madrid
RECRUITING
Queen Elizabeth Hospital, Birmingham
RECRUITING
Cambridge University Hospitals NHS Foundation Trust, Cambridge
RECRUITING
Royal Free London NHS Foundation Trust, London
RECRUITING
King's College Hospital NHS Foundation Trust, London
Quell Therapeutics Limited
INDUSTRY